Bridgewater Associates’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-11,119
| Closed | -$331K | – | 757 |
|
|
2024
Q4 | $331K | Sell |
11,119
-28,264
| -72% | -$842K | ﹤0.01% | 619 |
|
|
2024
Q3 | $616K | Sell |
39,383
-41,898
| -52% | -$655K | ﹤0.01% | 668 |
|
|
2024
Q2 | $1.39M | Sell |
81,281
-16,181
| -17% | -$277K | 0.01% | 605 |
|
|
2024
Q1 | $1.52M | Buy |
97,462
+11,286
| +13% | +$176K | 0.01% | 532 |
|
|
2023
Q4 | $1.29M | Buy |
86,176
+59,048
| +218% | +$882K | 0.01% | 601 |
|
|
2023
Q3 | $438K | Sell |
27,128
-88,098
| -76% | -$1.42M | ﹤0.01% | 700 |
|
|
2023
Q2 | $4.78M | Sell |
115,226
-12,518
| -10% | -$519K | 0.03% | 317 |
|
|
2023
Q1 | $7.68M | Sell |
127,744
-7,999
| -6% | -$481K | 0.05% | 243 |
|
|
2022
Q4 | $9.96M | Sell |
135,743
-30,759
| -18% | -$2.26M | 0.05% | 251 |
|
|
2022
Q3 | $12.7M | Buy |
166,502
+15,032
| +10% | +$1.14M | 0.06% | 215 |
|
|
2022
Q2 | $10.5M | Buy |
151,470
+15,190
| +11% | +$1.06M | 0.04% | 315 |
|
|
2022
Q1 | $11.3M | Buy |
136,280
+36,879
| +37% | +$3.06M | 0.05% | 278 |
|
|
2021
Q4 | $7.46M | Buy |
99,401
+3,295
| +3% | +$247K | 0.04% | 228 |
|
|
2021
Q3 | $11.2M | Sell |
96,106
-536
| -0.6% | -$62.3K | 0.06% | 188 |
|
|
2021
Q2 | $21.4M | Buy |
+96,642
| New | +$21.4M | 0.14% | 123 |
|